Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 373 followers
Latest posts
Last updated about 11 hours ago
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
about 11 hours ago
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost...
Invitation to Roche’s Half Year Results 2026 Presentation
6 days ago
Roche will publish its Half Year Results of 2026 prior to the...
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
11 days ago
Filing acceptance based on data from the phase III SUNMO study where...
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
18 days ago
Filing acceptance is based on the phase III Alliance ATOMIC study showing...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
21 days ago
Agreement offers potential best-in-class targeted protein degrader therapy option for people living...
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
27 days ago
Filing acceptance, under priority review, based on phase III data showing giredestrant...
Reminder: Invitation to Roche’s Virtual ADA Investor Event
28 days ago
We are pleased to invite investors and analysts to participate in our...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
28 days ago
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its...
Reminder: Invitation to Roche’s Investor Event at ASCO 2026
about 1 month ago
The Roche Investor Relations team would like to invite you to an...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
about 1 month ago
New giredestrant data from the lidERA study on its potential as a...
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
about 2 months ago
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with...
Invitation to Roche’s Virtual ADA Investor Event
about 2 months ago
We are pleased to invite investors and analysts to participate in our...